文献速递消化道肿瘤放疗

短程放疗为基础的全新辅助治疗后直肠癌器官保留

Organ preservation in rectal cancer following clinical complete response after short-course radiotherapy-based total neoadjuvant therapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-06-11

本回顾性队列纳入2020至2023年51例II-III期局部进展期直肠癌患者,均接受短程放疗(25 Gy/5次)序贯巩固化疗,8-12周后评估疗效;19例(37.3%)达临床完全缓解,18例(35.3%)进入观察等待。中位随访43.2个月,3例(16.7%)出现局部再生且均经R0手术成功挽救。

要点

  • 短程放疗为基础的TNT后37.3%患者达cCR,35.3%进入观察等待。
  • 观察等待者中16.7%出现局部再生,均经R0切除成功挽救。
  • 72.2%的观察等待患者维持持续cCR且无肿瘤学事件。

核心结论

  • 以短程放疗整合的全新辅助治疗策略可在部分局部进展期直肠癌患者中实现应答指导的器官保留,局部再生无生存率可接受,且可在公共医疗体系中实施。

研究设计与样本

  • 回顾性队列研究,纳入2020至2023年连续51例II-III期局部进展期直肠癌患者(cT3-T4和/或N+,可触及肿瘤距肛缘≤8 cm)。
  • 全部患者接受短程放疗(25 Gy分5次)后序贯巩固化疗(FOLFOX或CAPOX)。
  • TNT后8-12周通过直肠指检、盆腔MRI、软式乙状结肠镜和CEA水平评估肿瘤应答。
  • 达cCR者按结构化观察等待方案管理,其余行全直肠系膜切除(TME)。
  • 时间-事件结局采用描述性估计。

主要发现

  • 51例可评估患者中19例(37.3%)达cCR,18例(35.3%)接受观察等待管理。
  • 中位随访43.2个月(IQR 34.1-51.5),3例观察等待患者(16.7%)出现局部再生,均经R0切除成功挽救。
  • 估计24个月局部无再生生存率为82.2%(95%CI 65.8-100%)。
  • 1例观察等待患者在挽救手术后死于全身进展。
  • 手术组4例(12.1%)达病理完全缓解(pCR);18例观察等待患者中13例(72.2%)随访期间维持持续cCR且无肿瘤学事件。

关键数值与推荐

  • 短程放疗剂量为25 Gy分5次,随后行FOLFOX或CAPOX巩固化疗。
  • 肿瘤应答于TNT后8-12周评估;达cCR者进入结构化观察等待方案。

临床怎么用

  • 对短程放疗为基础TNT后达cCR的局部进展期直肠癌患者,可考虑应答指导的观察等待策略并结构化随访。
  • 局部再生经R0手术挽救仍可获得较好结局,需向患者说明随访与挽救手术的必要性。

局限性

  • 为单中心回顾性队列,样本量51例,时间-事件结局仅作描述性估计。
  • 随访时间中等,作者指出需前瞻性验证及更长随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Organ preservation after total neoadjuvant therapy (TNT) is feasible in patients with locally advanced rectal cancer (LARC) who achieve a clinical complete response (cCR). However, most watch-and-wait (WW) evidence derives from long-course chemoradiotherapy (LCCRT), with limited data regarding short-course radiotherapy (SCRT)-based TNT. We evaluated response-adapted organ preservation following SCRT-based TNT in a public, resource-limited healthcare setting. MATERIALS AND METHODS: This retrospective cohort included consecutive patients with stage II-III LARC (cT3-T4 and/or N+) with palpable tumors ≤8 cm from the anal verge treated between 2020 and 2023. All patients received SCRT (25 Gy in five fractions) followed by consolidation chemotherapy (FOLFOX or CAPOX). Tumor response was assessed 8-12 weeks after TNT using digital rectal examination, pelvic MRI, flexible sigmoidoscopy and CEA levels. Patients achieving a cCR were managed with a structured WW protocol; others underwent total mesorectal excision (TME). Time-to-event outcomes were estimated descriptively. RESULTS: Among 51 evaluable patients, 19 (37.3%) achieved cCR and 18 (35.3%) were managed with WW. After a median follow-up of 43.2 months (IQR 34.1-51.5), 3 WW patients (16.7%) developed local regrowth, all successfully salvaged with R0 resection. The estimated 24-month local regrowth-free survival was 82.2% (95% CI 65.8-100%). One WW patient died from systemic progression after salvage surgery. In the surgical group, 4 patients (12.1%) achieved a pathological complete response (pCR). Overall, 13 of 18 WW patients (72.2%) maintained sustained cCR without any oncologic event during follow-up. CONCLUSIONS: Hypofractionated SCRT integrated into a TNT strategy enabled response-adapted organ preservation with acceptable local regrowth-free survival in selected patients with LARC. This strategy was deliverable within a public healthcare system and achieved acceptable mid-term oncologic control. Prospective validation with longer follow-up is warranted.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Morales CG, Manriquez-Alegria E, Duran V, et al. Organ preservation in rectal cancer following clinical complete response after short-course radiotherapy-based total neoadjuvant therapy. Clin Transl Radiat Oncol. 2026. PMID: 42383069. doi:10.1016/j.ctro.2026.101216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。